Aurora Cannabis is expanding its reach in Australia’s medical marijuana market through a new distribution partnership between its subsidiary, MedReleaf Australia, and Leafio, the wholesale arm of Montu Australia.
The agreement positions Leafio to distribute Aurora’s lineup of medical marijuana brands through a nationwide pharmacy network, significantly widening patient access.
Aurora said Leafio will begin supplying products sold under MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co. and IndiMed to more than 4,000 pharmacies across the country. Company officials framed the partnership as a way to improve patient access and support clinicians with additional resources.
Stanley Sack, interim managing director of MedReleaf Australia, said the collaboration is designed to give more patients access to reliable, high-quality medical marijuana options. He noted that pairing Aurora’s TGA-GMP certified products with Leafio’s established role in medical distribution makes the partnership a natural fit.
Leafio General Manager Nicole Le Maistre said the expanded collaboration will strengthen Australia’s medical marijuana sector, pointing to potential benefits like more research, improved clinician education and expanded product availability. She said the companies will be able to reach more patients “through trusted medical channels.”
Aurora has been working to grow its international medical business, with operations in Canada, Europe, Australia and New Zealand. MedReleaf Australia serves as the company’s primary medical arm in the region, while Leafio oversees a large-scale distribution network for pharmacies seeking on-demand, Australia-wide access to medical marijuana products.
Under the new agreement, Aurora’s medical portfolio will enter Leafio’s daily dispatch system, which supplies pharmacies across the country. Doctors and healthcare professionals can contact MedReleaf Australia’s clinical support team for information about available products.
Both companies say the partnership is expected to support long-term growth in Australia’s regulated medical marijuana market, which continues to expand as more patients and clinicians adopt marijuana-based therapies.
More articles from The Marijuana Herald:
